Rohtak News Magazine

Urothelial Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

 Breaking News
  • No posts were found

Urothelial Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

March 13
20:24 2023
Urothelial Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

DelveInsight’s, “Urothelial Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in the Urothelial Carcinoma pipeline landscape. It covers the Urothelial Carcinoma pipeline drug profiles, including Urothelial Carcinoma clinical trials and nonclinical stage products. It also covers the Urothelial Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Urothelial Carcinoma Emerging drugs, the Urothelial Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Urothelial Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Urothelial Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Urothelial Carcinoma clinical trials studies, Urothelial Carcinoma NDA approvals (if any), and product development activities comprising the technology, Urothelial Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Urothelial Carcinoma Pipeline Report

 

  • DelveInsight’s Urothelial Carcinoma pipeline analysis depicts a robust space with 40+ active players working to develop 50+ pipeline treatment therapies

 

  • The leading urothelial carcinoma pipeline companies working to develop potential drug candidates to improve the urothelial carcinoma treatment scenario include Shandong TheraWisdom Biopharma Co., Ltd., Ikena Oncology, Ocellaris Pharma, Inc., Bayer, 4D Pharma PLC, MedPacto, QED Therapeutics, Bristol-Myers Squibb, Kyowa Kirin Pharmaceutical Development, Vyriad,Inc, Basilea Pharmaceutica, Pfizer, Daiichi Sankyo, Janssen Research & Development, LLC, Eli Lilly and Company, InnoCare Pharma, Kinnate Biopharma, Clovis Oncology, Gritstone Oncology, Xennials Therapeutics, Genome and Company , Exelixis, Atreca, Zentalis Pharmaceuticals, Celldex Therapeutics Inc , Nurix Therapeutics, Inc., Lipac Oncology LLC, TesoRx Pharma, LLC, Adaptimmune Therapeutics, Helsinn Group, Bicycle Therapeutics, Scholar Rock, Inc., Janux Therapeutics, Checkpoint Therapeutics, Inc., BioAtla, Inc., Cybrexa Therapeutics, Eisai Inc., Incyte Corporation, Shattuck Labs, Inc., Tempest Therapeutics, RAPT Therapeutics, Inc., Nektar Therapeutics, TAIHO PHARMACEUTICAL, Jazz Pharmaceuticals, Tyra Biosciences, Rubius Therapeutics, MacroGenics, BioNTech SE, Sorrento, and several others

 

  • Promising Urothelial carcinoma therapies such as OC-001, IK-175, MRx 518, Rogaratinib, Vactosertib, Infigratinib, TWP-101, Ipilimumab, KHK 2455, MV-NIS, Derazantinib, Sasanlimab, Trastuzumab deruxtecan, TAR-200, Ramucirumab, ICP-192, KIN-3248, Rucaparib, GRANITE 001, NTX-301, GEN-001, XL092, ATRC-101, ZN-c3, CDX-527, NX-1607, TSD-001, CK-301, BA3071, CBX-12, E7130, INCB099280, SL-279252, TPST-1495, FLX475, NKTR-255, TAS0313, Lurbinectedin, TYRA-300, RTX-224, Enoblituzumab, GEN1046, Sti-3031, and others.

 

  • The Urothelial carcinoma Companies and academics are working to assess challenges and seek opportunities that could influence Urothelial Carcinoma R&D. The Urothelial carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Diffuse Large B-Cell Lymphoma.

 

Request a sample and discover the recent breakthroughs happening in the Urothelial Carcinoma Pipeline landscape @ Urothelial Carcinoma Pipeline Outlook Report

 

Urothelial Carcinoma Overview

Urothelial carcinoma, also known as transitional cell carcinoma (TCC), is by far the most common type of bladder cancer. Urothelial carcinomas are the fourth most common tumors after prostate, lung and colorectal cancer. This carcinoma is derived from the urothelium of the upper urinary tract (renal pelvis and ureter) or lower urinary tract (urinary bladder). In contrast with bladder urothelial carcinomas, upper urinary tract urothelial carcinomas (UTUCs) are relatively rare and account for only 5 to 10% of urothelial carcinomas. Development of targeted therapies for urothelial carcinoma is still in early stages, consequently there have been no major therapeutic advances to date.

 

Recent Developmental Activities in the Urothelial Carcinoma Treatment Landscape

 

  • In May 2022, Exelixis, Inc. announced detailed results from multiple cohorts of Phase Ib COSMIC-021 trials of cabozantinib (CABOMETYX^®) as a monotherapy and in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. The company announced that they would be presenting the data from urothelial carcinoma (UC) cohorts 3, 4, and 5 and from non-small cell lung cancer (NSCLC) cohorts 7 and 20 during oral abstract sessions at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, IL, June 3–7

 

  • In May 2022, Kinnate Biopharma Inc. announced the presentation of the design and rationale of a Phase I trial-in-progress (KIN-4802, NCT05242822) evaluating the company’s pan-FGFR inhibitor product candidate, KIN-3248. The company announced that they would be presenting the details during a poster session on June 6, 2022, at the Annual Meeting of the American Society of Clinical Oncology (ASCO). In April 2022, Ikena Oncology, Inc. announced that it would be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The presentations will include overviews of the clinical trials for Ikena’s novel TEAD inhibitor, IK-930, and aryl hydrocarbon receptor (AHR) antagonist, IK-175

 

  • In March 2022, Juniper Biologics Pte Ltd and Helsinn Group, announced the signing of an exclusive license agreement to develop and commercialize infigratinib (INN) in Australia, New Zealand, Southeast Asia, and certain markets in the Middle East and Africa for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangements

 

  • Infigratinib is an orally administered, selective, ATP‐competitive, kinase inhibitor of FGFR 1, 2, and 3. The therapy is currently under investigation as a potential first-line treatment for individuals with unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with FGFR2 fusion/rearrangement and in the adjuvant setting for individuals with invasive urothelial carcinoma (bladder cancer) with susceptible FGFR3 genetic alterations

 

  • In April 2022, Bicycle Therapeutics plc announced interim Phase I results from the Phase I/II trial of BT8009, a second-generation BTC™ targeting Nectin-4. The results were presented in an oral presentation on Sunday, April 10, at the 2022 American Association for Cancer Research Annual Meeting in New Orleans, LA. 

 

For further information, refer to the detailed Urothelial Carcinoma Drugs Launch, Urothelial Carcinoma Developmental Activities, and Urothelial Carcinoma News, click here for Urothelial Carcinoma Ongoing Clinical Trial Analysis

 

Urothelial Carcinoma Emerging Drugs Profile

 

  • Pemazyre (pemigatinib): Incyte

Pemazyre (pemigatinib) is a kinase inhibitor indicated in the United States for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test9. In Japan, Pemazyre is approved for the treatment of patients with unresectable biliary tract cancer (BTC) with a fibroblast growth factor receptor 2 (FGFR2) fusion gene, worsening after cancer chemotherapy. Pemazyre is a potent, selective, oral inhibitor of FGFR isoforms 1, 2 and 3 which, in preclinical studies, has demonstrated selective pharmacologic activity against cancer cells with FGFR alterations.

 

  • Cetrelimab: Janssen Research and Development

Cetrelimab is a Janssen discovered and developed investigational programmed cell death receptor-1 (PD-1) monoclonal antibody being studied in the treatment of bladder cancer, prostate cancer, and multiple mye

 

Urothelial Carcinoma Pipeline Therapeutics Assessment

There are approx. 40+ key companies which are developing the therapies for Urothelial Carcinoma. The companies which have their Urothelial Carcinoma drug candidates in the most advanced stage, i.e. Phase III include Janssen Research and Development.

 

Find out more about the Urothelial Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Urothelial Carcinoma Emerging Drugs @ Urothelial Carcinoma Treatment Landscape

 

Scope of the Urothelial Carcinoma Pipeline Report

 

  • Coverage- Global

 

  • Urothelial Carcinoma Companies- Shandong TheraWisdom Biopharma Co., Ltd., Ikena Oncology, Ocellaris Pharma, Inc., Bayer, 4D Pharma PLC, MedPacto, QED Therapeutics, Bristol-Myers Squibb, Kyowa Kirin Pharmaceutical Development, Vyriad,Inc, Basilea Pharmaceutica, Pfizer, Daiichi Sankyo, Janssen Research & Development, LLC, Eli Lilly and Company, InnoCare Pharma, Kinnate Biopharma, Clovis Oncology, Gritstone Oncology, Xennials Therapeutics, Genome and Company , Exelixis, Atreca, Zentalis Pharmaceuticals, Celldex Therapeutics Inc , Nurix Therapeutics, Inc., Lipac Oncology LLC, TesoRx Pharma, LLC, Adaptimmune Therapeutics, Helsinn Group, Bicycle Therapeutics, Scholar Rock, Inc., Janux Therapeutics, Checkpoint Therapeutics, Inc., BioAtla, Inc., Cybrexa Therapeutics, Eisai Inc., Incyte Corporation, Shattuck Labs, Inc., Tempest Therapeutics, RAPT Therapeutics, Inc., Nektar Therapeutics, TAIHO PHARMACEUTICAL, Jazz Pharmaceuticals, Tyra Biosciences, Rubius Therapeutics, MacroGenics, BioNTech SE, Sorrento, and others. 

 

  • Urothelial Carcinoma Pipeline Therapies- OC-001, IK-175, MRx 518, Rogaratinib, Vactosertib, Infigratinib, TWP-101, Ipilimumab, KHK 2455, MV-NIS, Derazantinib, Sasanlimab, Trastuzumab deruxtecan, TAR-200, Ramucirumab, ICP-192, KIN-3248, Rucaparib, GRANITE 001, NTX-301, GEN-001, XL092, ATRC-101, ZN-c3, CDX-527, NX-1607, TSD-001, CK-301, BA3071, CBX-12, E7130, INCB099280, SL-279252, TPST-1495, FLX475, NKTR-255, TAS0313, Lurbinectedin, TYRA-300, RTX-224, Enoblituzumab, GEN1046, Sti-3031, and others.

 

  • Urothelial Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action 

 

Dive deep into rich insights for drugs for Urothelial Carcinoma Pipeline Companies and Therapies, click here @ Urothelial Carcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Urothelial Carcinoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Urothelial Carcinoma– DelveInsight’s Analytical Perspective
  7. Mid Stage Products (Phase III)
  8. Cetrelimab: Janssen Research and Development
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Vactosertib: MedPacto
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. Drug name: Company name
  15. Drug profiles in the detailed report…..
  16. Early Stage Products (Phase I)
  17. MV NIS: Vyriad
  18. Drug profiles in the detailed report…..
  19. Preclinical Stage Products
  20. Drug name: Company name
  21. Drug profiles in the detailed report…..
  22. Inactive Products
  23. Urothelial Carcinoma Key Companies
  24. Urothelial Carcinoma Key Products
  25. Urothelial Carcinoma- Unmet Needs
  26. Urothelial Carcinoma- Market Drivers and Barriers
  27. Urothelial Carcinoma- Future Perspectives and Conclusion
  28. Urothelial Carcinoma Analyst Views
  29. Urothelial Carcinoma Key Companies
  30. Appendix

 

Got Queries? Find out the related information on Urothelial Carcinoma Mergers and acquisitions, Urothelial Carcinoma Licensing Activities @ Urothelial Carcinoma Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/